Improved Management of Soft Tissue Sarcomas Patients With an Optimized and Innovative Sorting Technology for Circulating Tumor Cells

EXPERIMENTAL PLAN One archival tumor sample (any FFPE and/or frozen tumor sample from surgery specimen or biopsy) will be collected.

• A supplementary blood sample (2*10 mL EDTA) will be also collected: blood sample will be collected before anthracyclin treatment initiation and during a standart sample performed after validation of inclusion.
• Biological analyses will be initiated once inclusion has been confirmed (See Section 6.4)
• A supplementary blood sample (2*10 mL EDTA) will be also collected: blood sample will be collected before each chemotherapy administration and during a standart sample.
• A supplementary blood sample (2*10 mL EDTA) will be also collected: blood sample will be collected at each disease progression and during a standart sample.
• In case of disease progression and if a biopsy is required for the management of the patient, a tumor sample will be collected (if patient agreed and if pathological material is the sufficient).
• Clinical data will be collected into the study eCRF. Medical FU include visits at each chemotheapy administration, and disease assessment

A total of 100 patients will be enrolled.

Considering the nature of this trial, the sample size was defined in an empirical manner considering that over the 36-month enrollment period, 100 patients could be enrolled.

The percentage of patients with detectable CTC (primary criterion) will be given with its associateed 95% confidence interval. For the seondary criteria, qualitative variables will be described using frequency and percentage distributions. The number of missing data will be given, but will not be considered for the calculation of proportions. Quantitative data will be described using the number of observations, mean, standard deviation, median, minimum and maximum values.

Patient characteristics and other baseline data (demographics, disease characteristics) will be summarized.

All data analyses will be performed using the SAS version 9.4 statistical software

Inclusion criteria

• Male or female patients ≥ 18 years at the day of consenting;
• Histologically confirmed diagnosis of Soft Tissue Sarcoma (STS) excepted GIST.
• Metastatic disease or unresectable locally advanced malignancy for which standard therapy by anthracycline is decided;
• At least one measurable lesion as per RECIST version 1.1.;
• ECOG Performance Status of 0-2;
• Patients must have an adequate organ and bone marrow function at baseline;
• Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with procedures as per protocol;
• Covered by a medical insurance.

Exclusion criteria

• Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results;
• Prior treatment with anthracycline;
• History of other malignancy other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of disease for at least 3 years;
• Metabolic syndrome;
• Pregnant or breast-feeding woman criteria